BioOrbit, a London-based company, has raised $13.2 million to develop its in-space microgravity crystallization process for manufacturing pharmaceutical drugs, potentially allowing cancer therapies to be administered at home instead of in hospitals. The funding will support the company's transition to industrial deployment and the conversion of microgravity research into pharmaceutical programs.
BioOrbit's innovative use of microgravity crystallization in space to manufacture pharmaceutical drugs presents a significant opportunity for transforming cancer treatments into at-home, subcutaneous injections. This development could disrupt traditional intravenous administration, offering potential partnerships or investment opportunities in the burgeoning field of space-based drug manufacturing that addresses current limitations in antibody therapies.